Mitsubishi Ufj Trust & Banking Corp Bluebird Bio, Inc. Transaction History

Mitsubishi Ufj Trust & Banking Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $6.15 Million - $8.07 Million	-130,864 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$59.47 - $93.1 $1.84 Million - $2.88 Million	-30,934 Reduced 19.12%	130,864 $12 Million
Q2 2019 Aug 07, 2019	BUY	$75.84 - $105.21 $905,377 - $1.26 Million	11,938 Added 7.97%	161,798 $20.6 Million
Q1 2019 May 13, 2019	SELL	$64.44 - $104.11 $44,463 - $71,835	-690 Reduced 0.46%	149,860 $23.6 Million
Q4 2018 Feb 12, 2019	SELL	$59.1 - $93.26 $210,396 - $332,005	-3,560 Reduced 2.31%	150,550 $14.9 Million
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $313,675 - $414,739	3,530 Added 2.34%	154,110 $22.5 Million
Q2 2018 Aug 10, 2018	SELL	$99.64 - $127.59 $1.1 Million - $1.41 Million	-11,020 Reduced 6.82%	150,580 $23.6 Million
Q1 2018 May 11, 2018	SELL	$105.8 - $150.94 $792,442 - $1.13 Million	-7,490 Reduced 4.43%	161,600 $27.6 Million
Q4 2017 Feb 09, 2018	SELL	$81.25 - $130.7 $361,562 - $581,615	-4,450 Reduced 2.56%	169,090 $30.1 Million
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $10 Million - $15.9 Million	173,540	173,540 $23.8 Million

152

63.7M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $24.7M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Trust & Banking Corp, based on Form 13F filings with the SEC.

Stay updated on Mitsubishi Ufj Trust & Banking Corp with notifications on news.